Phylos is a Portland-based cannabis genetics company that applies modern plant-breeding techniques, large-scale field data, and rapid iteration to create uniform, high-yielding, and disease-resistant F1 hybrid cannabis cultivars. Its core product is a genetics platform that delivers reliable seed lines and a continuously expanding portfolio of genetically and phenotypically distinct hybrids aimed at improving consistency, scale, and quality for cultivators. The company emphasizes data-driven breeding to boost yield, predictability, and production efficiency across markets. Through long-standing collaboration with major producer Organigram, Phylos provides priority access to select genetics while continuing to broaden its offerings to the wider industry. The newly announced funding will accelerate development of new traits and seed lines and advance the company’s broader breeding roadmap. Although no revenue or user figures were disclosed, the press release positions Phylos as a key enabler of the next phase of large-scale, seed-based cannabis production driven by predictable genetics.

Total raised

$9M

Funding rounds

3

Latest round

Equity

Latest activity

Jul 2024